key: cord-1008791-5or25hej
authors: Lacroix, Isabelle; Bénévent, Justine; Damase-Michel, Christine
title: Chloroquine and hydroxychloroquine during pregnancy: what do we know?
date: 2020-05-11
journal: Therapie
DOI: 10.1016/j.therap.2020.05.004
sha: a799e007f97bf34724cc9a1423182ddd1f7fe9f9
doc_id: 1008791
cord_uid: 5or25hej

nan

J o u r n a l P r e -p r o o f What do we know about the safety of these medications in pregnant women? Chloroquine and hydroxychloroquine cross the placenta.

The volume of distribution of these medications is very high and potentially worrying for pregnant women and their half-lives are long; 10 to 30 days for chloroquine and 30 to 60 days for hydroxychloroquine, which leads to prolonged exposure after stopping these drugs. Thus, a woman who takes and stops one of these drugs before pregnancy can therefore be exposed during the upcoming pregnancy.

More data on safety during pregnancy are available about chloroquine, an old medication widely used in the general population as antimalarial than about hydroxychloroquine which is currently indicated for some autoimmune diseases such as lupus or rheumatoid arthritis.

First, experimental studies (in mice and monkeys) have shown that chloroquine could accumulate in the eyes, ears and adrenals. At very high doses (>250 mg / kg), microphthalmia and anophthalmia have been reported in rats. More recently, in "in vitro" and "in vivo" experiments, chloroquine caused genetic mutations and chromosomal damage (summary of product characteristics of Nivaquine ® ).

In humans, three studies on 169, 130 and 774 [1-3] women exposed to chloroquine during the 1st trimester of their pregnancy did not suggest an increase in the risks of congenital anomalies, in utero death or low birth weight.

Regarding hydroxychloroquine, two meta-analysis including 8 and 6 studies were published in 2015 and 2018 [4] [5] . Their conclusion are rather reassuring about the risks of teratogenicity, termination of pregnancy and prematurity. However, according to the authors, these data should be interpreted with caution because the studies included in these meta-analyses, only small numbers of pregnant women (9 to 383 pregnant women) and were often observational [6] .

Due to already described animal observations and rare but severe ocular adverse effects of both chloroquine and hydroxychloroquine in treated patients (retinal damage, sometimes irreversible, after several years of exposure), several case-studies have focused on the potential risk of prenatal exposure to chloroquine and hydroxychloroquine on eye development. Two cases of retinal degeneration after in utero exposure to chloroquine were published in 1969 [7] and 1 case of ocular abnormality in 2011 [8] in a child exposed prenatally to methotrexate and chloroquine. Two reviews of 12 and 9 studies [7, 9] including respectively 588 and 246 children did not highlight an increased risk of eye abnormalities in children exposed in utero to the two medications of interest. However, the authors of the reviews underlined the insufficiency of data, the presence of numerous biases and the need to follow up the children over a longer period. The ocular toxicity of these 2 drugs is dependent on the "dose" and the "duration of use" [10] . Considering the half-lives of these drugs, one cannot exclude, in case of a long exposure, their accumulation, favouring adverse effects on the retina.

In conclusion, clinical data on chloroquine and hydroxychloroquine in pregnant women are rather reassuring when used in the indications of their marketing authorization. Some data exist with chloroquine when it is used against malaria. In other situations (other dosages, other durations of treatment, other indications), their benefit / risk balance is not established yet. These drugs can induce adverse effects, on the eyes (and a rare risk for the foetus cannot be entirely ruled out), but also on the heart rhythm (they are quinidine derivatives) that must increase our vigilance. In addition, chloroquine and potentially hydroxychloroquine are genotoxic.

The use of these medications in pregnant women should therefore only be considered if the benefit of their use clearly justifies it.

Given the half-lives of these drugs, it should also be remembered that a woman who took one of these 2 drugs will remain exposed up to 210 days for chloroquine and 420 days for hydroxychloroquine after stopping their intake. Thus, a woman who takes and stops one of these drugs before pregnancy can therefore be exposed during the upcoming pregnancy. In the case of exposure during pregnancy, as a precaution, careful ultrasound monitoring, increased vigilance at birth (especially in case of prematurity) and ophthalmological monitoring of the child should be recommended.

The authors declare that they have no competing interest

Safety of chloroquine in chemosuppression of malaria during pregnancy

The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy

Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: A systematic review and meta-analysis

Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis

Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature

The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine

Hydroxychloroquine during pregnancy: a review of retinal toxicity in the newborns

Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update